Glaxo claims bird flu breakthrough

CNN.com/Reuters - Thursday July 26, 2007
Artlce Link

LONDON, England (Reuters) -- A bird flu vaccine for humans that uses only a very low dose of active ingredient has proved effective in clinical tests and could be available in 2007, its maker GlaxoSmithKline Plc has said.

The promising result means Europe's biggest pharmaceuticals group is on track to start making the vaccine in commercial quantities by the end of the year.

Glaxo believes its H5N1 vaccine will work more efficiently than rival ones in development because of the proprietary adjuvant used in its manufacture. Adjuvants are additives put into vaccines that boost the immune system and make it respond more efficiently.

This website is intended for informational purposes only and is not in any way affiliated with the military.

Website designed and maintained by HealthSentinel.com